A5024024241- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Testicular diseases and treatments
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Renal and related cancers
- PARP inhibition in cancer therapy
- Esophageal Cancer Research and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Urologic and reproductive health conditions
- Ovarian cancer diagnosis and treatment
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Myasthenia Gravis and Thymoma
- Intraperitoneal and Appendiceal Malignancies
- Neuroendocrine Tumor Research Advances
- Drug-Induced Adverse Reactions
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
- Hormonal and reproductive studies
Vita-Salute San Raffaele University
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024-2025
IRCCS Ospedale San Raffaele
2023-2024
University College London
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2024
Azienda USL di Bologna
2021-2023
University of Bologna
2021-2023
Policlinico S.Orsola-Malpighi
2020-2021
732 Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of urothelial carcinoma (UC) across clinical stages. Several ICIs been approved by regulatory agencies for both adjuvant and metastatic settings. Limited information is available regarding efficacy rechallenge with ICI following progression on prior ICI-based therapy. We hypothesized that could be effective in selected pts UC. Methods: A retrospective study was performed using TriNetX analytics...
244 Background: The addition of androgen receptor pathway inhibitors (ARPI) to deprivation therapy (ADT) has improved survival in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC), both as doublets and triplets docetaxel. prognostic role genomic alterations (GA) is growing interest this setting. We evaluated the GA profiling a population treated ARPI-based single-center institution. Methods: Our retrospective analysis included mHSPC at IRCCS San Raffaele Hospital...
798 Background: In patients (pts) with MIBC, optimizing clinical staging (cT-stage) and response assessment after neoadjuvant therapies has become critical in order to envision next-generation bladder-sparing strategies. We have previously reported on the performance of bladder MRI stage predict pathological pembrolizumab use modified vesical-imaging reporting data system (VI-RADS, PMID: 37803523). Using ctDNA yields potential increase prediction stage, improve accuracy complete (cCR)...
553 Background: There is limited data in the literature concerning management of patients (pts) with metachronous oligometastatic RCC. This study aimed to compare survival outcomes various therapeutic modalities from a referral center cohort database. Methods: Pts recurrent RCC previous radical surgery for localized tumor, presenting ≤5 metastatic lesions, were retrospectively analyzed. The primary endpoint was progression-free (PFS). Secondary endpoints overall (OS) and PFS subsequent...
843 Background: Sex-specific differences in incidence, stage, and prognosis of have raised interest the role sex steroid hormones pathogenesis treatment response MIBC. Emerging evidence supports involvement both androgen estrogen pathways We previously identified receptor pathway as a negative predictive biomarker for neoadjuvant immunotherapy (Tateo et al. GU-ASCO24). However, little is known about (ER) pathway. Methods: In this unplanned post-hoc analysis PURE-01 study, we evaluated...
To evaluate the predictive capability of pre- and post-pembrolizumab Vesical Imaging-Reporting Data System (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder cancer (MIBC) within PURE-01 trial (ClinicalTrials.gov identifier: NCT02736266).
Yolk sac tumour postpubertal-type (YSTpt) shows a wide range of histological patterns and is challenging to diagnose. Recently, forkhead box transcription factor A2 (FoxA2) emerged as driver YSTpt formation promising marker for diagnosing YSTpt. However, FoxA2 has not been tested in the different This study aimed assess staining pattern te other germ cell tumours testis (GCTT), comparing it with glypican-3 (GPC3) α-fetoprotein (AFP).FOXA2, GPC3 AFP immunohistochemistry was performed on 24...
PURPOSE To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) postsurgical adjuvant in patients muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS Eligible had an Eastern Cooperative Oncology Group performance status ≤1 a T2-4aN0-1M0 stage >50% urothelial carcinoma histology were ineligible for or refused cisplatin-based chemotherapy. Patients received four cycles 360 mg once every 3 weeks + 125 mg/m 2 on...
LBA4517 Background: SG is an antibody-drug conjugate composed of anti-trophoblast cell surface antigen 2 (Trop-2) antibody coupled to SN-38 (a topoisomerase-I inhibitor) with US FDA-accelerated approval for locally advanced or metastatic urothelial carcinoma (mUC). A multi-cohort, open-label, phase SURE study evaluating neoadjuvant (SURE-01, NCT05226117) SG+pembrolizumab followed by adjuvant pembrolizumab (SURE-02, NCT05535218) in MIBC a flexible design allowing bladder-sparing approach. We...